Neviah Genomics is the inventor and developer of PropheTox, a drug toxicity screening service. Based on the mathematical analysis of cell behavior following exposure to multiple toxic and non-toxic compounds, PropheTox's innovatve assay design and optimized decision support algorithms allow the detection of low-dose, chronic toxic effects.
The predictive quality of the PropheTox technology is developed through an iterative process involving toxicity assays, machine learning, and prior biological knowledge.
The predictor is based on non-trivial analysis of expression data from experiments exposing primary liver cells to compounds with known toxicity, and representing a wide variety of liver toxicity pathways.